JPM 2026 Insights
Cyagen | February 05, 2026
JPM 2026 Insights by Cyagen
AI Transformation, Globalization 2.0, and Emerging Innovations in Core Modalities from Next-Gen ADCs to Degrader-Antibody Conjugates (DACs)
Contents
Overview
Derived from a comprehensive analysis of 109 industry leaders at the 44th J.P. Morgan Healthcare Conference, this report distills four pivotal trends: AI-driven transformation, platform expansion, patient-centricity, and the targeting of undruggable proteins. We provide a deep dive into high-growth arenas like Oncology and Metabolic diseases (specifically the next-gen GLP-1 landscape) and offer forward-looking perspectives on ADC, DAC, and RNA innovations. This report serves as a strategic compass for pharmaceutical R&D and investment decision-making.
Key Insights
Content
- JPM 2026 Overview
- Key Industry Trends
- Targets, Areas & Therapies
- Hot & Potential Directions
Subscribe to Receive Updates & Promotions From Cyagen
Subscribe
* Your privacy matters to us. We never share it with third parties.
Explore More
Ready to Elevate Your Research?
Discover how Cyagen can support your research. Let’s start a conversation.